O
OrbiMed Portfolio holdings
AUM
$3.98B
This Quarter Return
-10.39%
1 Year Return
+13.05%
3 Year Return
+159.74%
5 Year Return
+207.27%
10 Year Return
+1,027.33%
AUM
$5.91B
AUM Growth
+$5.91B
(-15%)
Cap. Flow
-$46.9M
Cap. Flow
% of AUM
-0.79%
Top 10 Holdings %
Top 10 Hldgs %
34.46%
Holding
169
New
32
Increased
33
Reduced
28
Closed
26
Top Buys
| 1 |
Arcutis Biotherapeutics
ARQT
|
$139M |
| 2 |
Biogen
BIIB
|
$132M |
| 3 |
Passage Bio
PASG
|
$110M |
| 4 |
Pfizer
PFE
|
$98.3M |
| 5 |
Gilead Sciences
GILD
|
$85.6M |
Top Sells
| 1 |
THOR
Synthorx, Inc. Common Stock
THOR
|
$372M |
| 2 |
ARQL
Arqule Inc
ARQL
|
$99.8M |
| 3 |
Danaher
DHR
|
$98.1M |
| 4 |
Regeneron Pharmaceuticals
REGN
|
$93.8M |
| 5 |
Tandem Diabetes Care
TNDM
|
$68M |
Sector Composition
| 1 | Healthcare | 97.58% |
| 2 | Financials | 1.89% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Humana
HUM
$36.5B
| $88M | 1.48% | 280,300 -111,600 | -28% | -$35M |
|
27
Intuitive Surgical
ISRG
$170B
| $83.7M | 1.41% | 169,100 +1,300 | +0.8% | +$644K |
|
28
Centene
CNC
$14.3B
| $79.4M | 1.33% | +1,335,700 | New | +$79.4M |
|
29
Cigna
CI
$80.3B
| $77.9M | 1.31% | 439,700 -50,000 | -10% | -$8.86M |
|
|
BLU
30
DELISTED
BELLUS Health Inc.
BLU
| $69.4M | 1.17% | 7,025,832 | – | – |
|
|
HZNP
31
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $69.4M | 1.17% | 2,341,700 +759,400 | +48% | +$22.5M |
|
32
HCA Healthcare
HCA
$94.5B
| $63.8M | 1.07% | 709,800 +519,800 | +274% | +$46.7M |
|
33
Stryker
SYK
$150B
| $61.8M | 1.04% | +371,100 | New | +$61.8M |
|
34
Agios Pharmaceuticals
AGIO
$2.19B
| $58.6M | 0.99% | +1,652,696 | New | +$58.6M |
|
35
Exelixis
EXEL
$10.1B
| $54.8M | 0.92% | 3,180,100 -573,600 | -15% | -$9.88M |
|
36
PTC Therapeutics
PTCT
$3.92B
| $51.2M | 0.86% | 1,148,723 -580,477 | -34% | -$25.9M |
|
37
MeiraGTx Holdings
MGTX
$587M
| $48.1M | 0.81% | 3,582,320 +129,300 | +4% | +$1.74M |
|
38
Glaukos
GKOS
$5.5B
| $47.8M | 0.8% | 1,547,646 | – | – |
|
|
DCPH
39
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $47.7M | 0.8% | 1,157,600 -356,571 | -24% | -$14.7M |
|
40
KALA BIO
KALA
$78.8M
| $47.5M | 0.8% | 5,402,730 +1,954,890 | +57% | +$17.2M |
|
41
uniQure
QURE
$896M
| $46.7M | 0.78% | 983,979 -97,786 | -9% | -$4.64M |
|
42
BioMarin Pharmaceuticals
BMRN
$11.2B
| $45.7M | 0.77% | 540,500 +505,800 | +1,458% | +$42.7M |
|
43
Enliven Therapeutics
ELVN
$1.2B
| $43.6M | 0.73% | +2,719,902 | New | +$43.6M |
|
44
Applied Therapeutics
APLT
$71M
| $43.1M | 0.73% | 1,319,877 +332,691 | +34% | +$10.9M |
|
45
Arvinas
ARVN
$568M
| $40.1M | 0.67% | 995,000 -903,800 | -48% | -$36.4M |
|
46
Bausch Health
BHC
$2.74B
| $37.2M | 0.63% | 2,399,880 -783,220 | -25% | -$12.1M |
|
47
Adverum Biotechnologies
ADVM
$64.6M
| $33.7M | 0.57% | 3,450,644 -891,546 | -21% | -$8.71M |
|
48
Edwards Lifesciences
EW
$47.8B
| $33.3M | 0.56% | 176,800 -258,100 | -59% | -$48.7M |
|
|
LOGC
49
DELISTED
LogicBio Therapeutics, Inc. Common Stock
LOGC
| $31.9M | 0.54% | 6,466,783 | – | – |
|
50
Thermo Fisher Scientific
TMO
$186B
| $31.3M | 0.53% | 110,300 -110,200 | -50% | -$31.3M |
|